Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2...

Related Keywords

United States ,Americans ,America ,American ,Julie Masow ,Sloan Simpson ,Susanne Schaffert ,Rachel Levine ,Jamie Bearse ,Oliver Sartor ,Prnewswire Novartis ,Twitter ,Accelerator Applications United States Inc ,Novartis Company ,Drug Administration ,Tulane Cancer Center ,Novartis ,Exchange Commission ,Novartis Pharmaceuticals Corporation ,Nj Novartis Pharmaceuticals Corporation ,European Medicines Agency ,American Cancer Society ,Multichannel News Release ,Medical Director ,Tulane Cancer ,Advanced Accelerator Applications ,Prescribing Information ,Phenotypic Precision Medicine ,Advanced Prostate ,Prostate Cancer ,Accelerator Applications ,Positron Emission ,Single Photon Emission Computed Tomography ,East Hanover ,Pharmaceuticals Corporation ,Advanced Accelerator Applications United States ,Nucl Med ,